BridgeMD
New treatment option for Mesothelin-Expressing Tumors
Official title CT-95 in Advanced Cancers Associated With Mesothelin Expression
ClinicalTrials.gov ID: NCT06756035
What this study is testing
What is CT-95?
CT-95 is an investigational medicine, given as an once-weekly infusion into a vein, being studied as a potential treatment for mesothelin-expressing tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with MSLN expression.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- ECOG 0 or 1
- people with evaluable disease per RECIST 1.1 or mRECIST
- people with adequate organ function.
- people with advanced cancers associated with mesothelin expression
You likely can't join if
- Uncontrolled significant active infection or any medical or other condition that in opinion of the investigator would preclude the subject's...
- Prior treatment with MSLN-targeted CD3 or chimeric antigen receptor T cell (CAR-T) therapy
- Concurrent participation in another investigational clinical trial.
- Evidence of leptomeningeal disease
The study team makes the final eligibility decision.
Where it's taking place
- Denver, Colorado, United States
- Chicago, Illinois, United States
- Grand Rapids, Michigan, United States
- Hackensack, New Jersey, United States
- Philadelphia, Pennsylvania, United States
- Nashville, Tennessee, United States
- San Antonio, Texas, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Denver, Colorado, United States; Chicago, Illinois, United States; Grand Rapids, Michigan, United States; Hackensack, New Jersey, United States; Philadelphia, Pennsylvania, United States; Nashville, Tennessee, United States and 1 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.